Das uveale Melanom – standardisiertes Vorgehen in Diagnostik, Therapie und Nachsorge

Zusammenfassung

Hintergrund Für das uveale Melanom fehlt als seltene onkologische Erkrankung derzeit in Deutschland eine nationale evidenzbasierte Leitlinie. Bis diese erstellt wird, bietet sich eine zentrumsübergreifende Standard Operating Procedure (SOP) an. Ziel des Projektes war die Erarbeitung einer konsentierten SOP zur Diagnostik, Therapie und Nachsorge des uvealen Melanoms im Rahmen des Netzwerkes Onkologischer Spitzenzentren, die von der Deutschen Krebshilfe gefördert werden.

Ergebnisse und Schlussfolgerung In einem auf dem aktuellen Wissensstand basierenden mehrstufigen Prozess eines moderierten Konsensusverfahrens konnte eine konsentierte SOP für die Diagnostik, Therapie und Nachsorge des uvealen Melanoms erarbeitet werden.

Schlüsselwörter

uveales Melanom - Aderhautmelanom - Irismelanom - Brachytherapie - Protonenbestrahlung - SOP

Publication History

Received: 18 March 2021

Accepted: 21 June 2021

Article published online:
10 August 2021

• References/Literatur

• 1 Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973–1997. Ophthalmology 2003; 110: 956-961
• 2 Egan KM, Seddon JM, Glynn RJ. et al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988; 32: 239-251
• 3 Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology 2012; 119: 1582-1589
• 4 Smith JH, Padnick-Silver L, Newlin A. et al. Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi. Ophthalmology 2007; 114: 774-779
• 5 Cheung M, Talarchek J, Schindeler K. et al. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet 2013; 206: 206-210
• 6 AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancerʼs 7th Edition Classification of Uveal Melanoma. JAMA Ophthalmol 2015; 133: 376-383
• 7 Kujala E, Damato B, Coupland SE. et al. Staging of ciliary body and choroidal melanomas based on anatomic extent. J Clin Oncol 2013; 31: 2825-2831
• 8 Coupland SE, Lake SL, Zeschnigk M. et al. Molecular pathology of uveal melanoma. Eye (Lond) 2013; 27: 230-242
• 9 van de Nes JA, Nelles J, Kreis S. et al. Comparing the Prognostic Value of BAP1 Mutation Pattern, Chromosome 3 Status, and BAP1 Immunohistochemistry in Uveal Melanoma. Am J Surg Pathol 2016; 40: 796-805
• 10 Vergara IA, Wilmott JS, Long GV. et al. Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape. Exp Dermatol 2021; DOI: 10.1111/exd.14287.
• 11 Decatur CL, Ong E, Garg N. et al. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes. JAMA Ophthalmol 2016; 134: 728-733
• 12 Onken MD, Worley LA, Long MD. et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008; 49: 5230-5234
• 13 Van Raamsdonk CD, Griewank KG, Crosby MB. et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363: 2191-2199
• 14 Van Raamsdonk CD, Bezrookove V, Green G. et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457: 599-602
• 15 Prescher G, Bornfeld N, Horsthemke B. et al. Chromosomal aberrations defining uveal melanoma of poor prognosis. Lancet 1992; 339: 691-692
• 16 Harbour JW, Onken MD, Roberson ED. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330: 1410-1413
• 17 Martin M, Masshofer L, Temming P. et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 2013; 45: 933-936
• 18 Yavuzyigitoglu S, Koopmans AE, Verdijk RM. et al. Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases. Ophthalmology 2016; 123: 1118-1128
• 19 Onken MD, Worley LA, Char DH. et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012; 119: 1596-1603
• 20 Prescher G, Bornfeld N, Hirche H. et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347: 1222-1225
• 21 Rodrigues M, Ait Rais K, Salviat F. et al. Association of Partial Chromosome 3 Deletion in Uveal Melanomas With Metastasis-Free Survival. JAMA Ophthalmol 2020; 138: 182-188
• 22 Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res 2010; 16: 6083-6092
• 23 Aughton K, Kalirai H, Coupland SE. MicroRNAs and Uveal Melanoma: Understanding the Diverse Role of These Small Molecular Regulators. Int J Mol Sci 2020; 21: 5648 DOI: 10.3390/ijms21165648.
• 24 Le Guin CHD, Metz KA, Lehmann N. et al. Chromosome 3 is a valid marker for prognostic testing of biopsy material from uveal melanoma later treated by brachytherapy. Biomarkers 2019; 24: 134-140
• 25 Moy CS, Albert DM, Diener-West M. et al. Cause-specific mortality coding. methods in the collaborative ocular melanoma study coms report no. 14. Control Clin Trials 2001; 22: 248-262
• 26 Leyvraz S, Piperno-Neumann S, Suciu S. et al. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC18021): a multicentric randomized trial. Ann Oncol 2014; 25: 742-746
• 27 Garg G, Finger PT, Kivelä TT. et al. Patients presenting with metastases: stage IV uveal melanoma, an international study. Br J Ophthalmol 2021; DOI: 10.1136/bjophthalmol-2020-317949.
• 28 Rantala ES, Hernberg MM, Lundin M. et al. Metastatic uveal melanoma managed with best supportive care. Acta Oncol 2021; 60: 135-139
• 29 Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res 2019; 29: 561-568
• 30 Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C. et al. Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients. Ophthalmic Res 2006; 38: 255-260
• 31 Gragoudas ES, Lane AM, Regan S. et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol 2000; 118: 773-778
• 32 Char DH, Quivey JM, Castro JR. et al. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology 1993; 100: 1547-1554
• 33 Singh AD, Kivela T. The collaborative ocular melanoma study. Ophthalmol Clin North Am 2005; 18: 129-142 ix
• 34 Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006; 124: 1684-1693
• 35 Rao PK, Barker C, Coit DG. et al. NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. J Natl Compr Canc Netw 2020; 18: 120-131
• 36 Chau C, van Doorn R, van Poppelen NM. et al. Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines. Cancers (Basel) 2019; 11: 1114
• 37 Mathis T, Cassoux N, Tardy M. et al. [Management of uveal melanomas, guidelines for oncologists]. Bull Cancer 2018; 105: 967-980
• 38 Barker CA, Salama AK. New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma. J Natl Compr Canc Netw 2018; 16: 646-650
• 39 Nathan P, Cohen V, Coupland S. et al. Uveal Melanoma UK National Guidelines. Eur J Cancer 2015; 51: 2404-2412
• 40 American Brachytherapy Society – Ophthalmic Oncology Task Force, ABS – OOTF Committee. Electronic address pec, Committee AO. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 2014; 13: 1-14
• 41 Seth R, Messersmith H, Kaur V. et al. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol 2020; 38: 3947-3970
• 42 Weis E, Salopek TG, McKinnon JG. et al. Management of uveal melanoma: a consensus-based provincial clinical practice guideline. Curr Oncol 2016; 23: e57-e64
• 43 Glossmann JP, Skoetz N, Starbatty B. et al. [Conjunctival melanoma: Standard operating procedures in diagnosis, treatment and follow-up care]. Ophthalmologe 2018; 115: 489-498
• 44 Seider MI, Berry DE, Schefler AC. et al. Multi-center analysis of intraocular biopsy technique and outcomes for uveal melanoma: Ocular Oncology Study Consortium report 4. Graefes Arch Clin Exp Ophthalmol 2020; 258: 427-435
• 45 Bagger MM. Intraocular biopsy of uveal melanoma Risk assessment and identification of genetic prognostic markers. Acta Ophthalmol 2018; 96 (Suppl. 112) S1-S28
• 46 Harbour JW. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. Methods Mol Biol 2014; 1102: 427-440
• 47 Harbour JW, Chao DL. A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. Ophthalmology 2014; 121: 1281-1288
• 48 Grisanti S, Ranjbar M, Tura A. et al. [Uveal melanoma: Early detection as the key to successful personalized medicine]. Ophthalmologe 2020; 117: 508-520
• 49 Tarmann L, Wackernagel W, Avian A. et al. Ruthenium-106 plaque brachytherapy for uveal melanoma. Br J Ophthalmol 2015; 99: 1644-1649
• 50 Rouberol F, Roy P, Kodjikian L. et al. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 yearsʼ experience with beta-rays). Am J Ophthalmol 2004; 137: 893-900
• 51 Seregard S, aft Trampe E, Lax I. et al. Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma. The Swedish experience. Acta Ophthalmol Scand 1997; 75: 11-16
• 52 Summanen P, Immonen I, Kivela T. et al. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma. Br J Ophthalmol 1996; 80: 732-739
• 53 Gragoudas ES. Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture. Invest Ophthalmol Vis Sci 2006; 47: 4666-4673
• 54 Echegaray JJ, Bechrakis NE, Singh N. et al. Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose. Ocul Oncol Pathol 2017; 3: 193-198
• 55 Kosydar S, Robertson JC, Woodfin M. et al. Systematic Review and Meta-Analysis on the Use of Photon-based Stereotactic Radiosurgery Versus Fractionated Stereotactic Radiotherapy for the Treatment of Uveal Melanoma. Am J Clin Oncol 2021; 44: 32-42
• 56 Parker T, Rigney G, Kallos J. et al. Gamma knife radiosurgery for uveal melanomas and metastases: a systematic review and meta-analysis. Lancet Oncol 2020; 21: 1526-1536
• 57 Biewald E, Lautner H, Gok M. et al. Endoresection of large uveal melanomas: clinical results in a consecutive series of 200 cases. Br J Ophthalmol 2017; 101: 204-208
• 58 Suesskind D, Scheiderbauer J, Buchgeister M. et al. Retrospective evaluation of patients with uveal melanoma treated by stereotactic radiosurgery with and without tumor resection. JAMA Ophthalmol 2013; 131: 630-637
• 59 Liegl R, Schmelter V, Fuerweger C. et al. Robotic CyberKnife Radiosurgery for Ciliary Body Melanoma. Ophthalmol Retina 2020; 4: 954-956
• 60 Groenewald C, Konstantinidis L, Damato B. Effects of radiotherapy on uveal melanomas and adjacent tissues. Eye (Lond) 2013; 27: 163-171
• 61 Blatsios G, Haas G, Zehetner C. et al. [Surgical Methods in the Treatment of Uveal Melanoma]. Klin Monbl Augenheilkd 2017; 234: 874-885
• 62 Seibel I, Riechardt AI, Heufelder J. et al. Adjuvant Ab Interno Tumor Treatment After Proton Beam Irradiation. Am J Ophthalmol 2017; 178: 94-100
• 63 Willerding GD, Cordini D, Moser L. et al. Neoadjuvant proton beam irradiation followed by transscleral resection of uveal melanoma in 106 cases. Br J Ophthalmol 2016; 100: 463-467
• 64 Damato B, Kacperek A, Errington D. et al. Proton beam radiotherapy of uveal melanoma. Saudi J Ophthalmol 2013; 27: 151-157
• 65 Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C. et al. Treatment of uveal melanoma by accelerated proton beam. Dev Ophthalmol 2012; 49: 41-57
• 66 Gunduz K, Bechrakis NE. Exoresection and endoresection for uveal melanoma. Middle East Afr J Ophthalmol 2010; 17: 210-216
• 67 Bechrakis NE, Petousis V, Willerding G. et al. Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate. Br J Ophthalmol 2010; 94: 460-466
• 68 Bechrakis NE, Petousis V, Krause L. et al. [Surgical treatment modalities in uveal melanomas]. Klin Monbl Augenheilkd 2009; 226: 921-926
• 69 Bechrakis NE, Hocht S, Martus P. et al. [Endoresection following proton beam irradiation of large uveal melanomas]. Ophthalmologe 2004; 101: 370-376
• 70 Shields CL, Dalvin LA, Chang M. et al. Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals. JAMA Ophthalmol 2020; 138: 136-146
• 71 Oxenreiter MM, Lane AM, Aronow MB. et al. Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field). Br J Ophthalmol 2020; DOI: 10.1136/bjophthalmol-2020-318063.
• 72 Leblanc A, Lumbroso-Le Rouic L, Desjardins L. et al. Diffuse Iris Melanoma: Conservative Treatment with Proton Beam Therapy after Limbal Stem Cell Preservation or Enucleation?. Ocul Oncol Pathol 2019; 5: 396-401
• 73 Riechardt AI, Klein JP, Cordini D. et al. Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects. Graefes Arch Clin Exp Ophthalmol 2018; 256: 1325-1332
• 74 Naumann GO, Rummelt V. Block excision of tumors of the anterior uvea. Report on 68 consecutive patients. Ophthalmology 1996; 103: 2017-2027 discussion 2027–2028
• 75 Rowcroft A, Loveday BPT, Thomson BNJ. et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford) 2020; 22: 497-505
• 76 Seregard S, Landau I. Transpupillary thermotherapy as an adjunct to ruthenium plaque radiotherapy for choroidal melanoma. Acta Ophthalmol Scand 2001; 79: 19-22
• 77 Tagliaferri L, Pagliara MM, Fionda B. et al. Personalized re-treatment strategy for uveal melanoma local recurrences after interventional radiotherapy (brachytherapy): single institution experience and systematic literature review. J Contemp Brachytherapy 2019; 11: 54-60
• 78 Riechardt AI, Cordini D, Dobner B. et al. Salvage proton beam therapy in local recurrent uveal melanoma. Am J Ophthalmol 2014; 158: 948-956
• 79 Cohen Y, Goldenberg-Cohen N, Parrella P. et al. Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 2876-2878
• 80 Mariani P, Piperno-Neumann S, Servois V. et al. Surgical management of liver metastases from uveal melanoma: 16 yearsʼ experience at the Institut Curie. Eur J Surg Oncol 2009; 35: 1192-1197
• 81 Ponti A, Denys A, Digklia A. et al. First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver. J Nucl Med 2020; 61: 350-356
• 82 Sussman TA, Funchain P, Singh A. Clinical Trials in Metastatic Uveal Melanoma: Current Status. Ocul Oncol Pathol 2020; 6: 381-387
• 83 Khoja L, Atenafu EG, Suciu S. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol 2019; 30: 1370-1380
• 84 Pelster MS, Gruschkus SK, Bassett R. et al. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. J Clin Oncol 2021; 39: 599-607 DOI: 10.1200/JCO.20.00605.
• 85 Damato BE, Dukes J, Goodall H. et al. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers (Basel) 2019; 11: 971